

# Contents

Preface.....	vii
Contributors .....	ix
<b>Chapter 1</b> Introduction: Scientific Factors in Biosimilar Product Development .....	1
<i>Laszlo Endrenyi, Paul Declerck, and Shein-Chung Chow</i>	
<b>Chapter 2</b> Analytical Characterization: Structural Assessment of Biosimilarity.....	15
<i>Steven A. Berkowitz</i>	
<b>Chapter 3</b> Analytical Similarity Assessment.....	83
<i>Shein-Chung Chow and Li Liu</i>	
<b>Chapter 4</b> Characterization of Biosimilar Biologics: The Link between Structure and Functions .....	109
<i>Roy Jefferis</i>	
<b>Chapter 5</b> Manufacturing and Process Control Issues: Quality Development of Biosimilar Medicinal Products.....	151
<i>Alan Fauconnier and Lyudmil Antonov</i>	
<b>Chapter 6</b> Nonclinical Studies for Biosimilars .....	175
<i>Karen De Smet and Leon AGJM van Aerts</i>	
<b>Chapter 7</b> The Clinical Development of Biosimilar Drugs .....	197
<i>Mark McCamish, Gillian Woollett, and Sigrid Balsler</i>	
<b>Chapter 8</b> Statistical Methods for Assessing Biosimilarity .....	219
<i>Shein-Chung Chow and Fuyu Song</i>	
<b>Chapter 9</b> Extrapolation of Indications for Biosimilars: Opportunity for Developers and Challenges for Regulators .....	263
<i>Jian Wang, Wallace Lauzon, Catherine Njue, and Agnes V. Klein</i>	

<b>Chapter 10</b>	Interchangeability, Switchability, and Substitution of Biosimilar Products.....	283
	<i>Paul Declerck, Laszlo Endrenyi, and Shein-Chung Chow</i>	
<b>Chapter 11</b>	Design and Analysis of Studies for Assessing Interchangeability.....	297
	<i>Shein-Chung Chow and Laszlo Endrenyi</i>	
<b>Chapter 12</b>	The Role of the Immunogenicity Evaluation for Biosimilars .....	323
	<i>Paul Chamberlain</i>	
<b>Chapter 13</b>	Pharmacovigilance of Biosimilars .....	361
	<i>Shehla Hashim, Souleh Semalulu, Felix Omara, and Duc Vu</i>	
<b>Chapter 14</b>	Patent Exclusivities Affecting Biosimilars in the United States, Canada, and Europe .....	375
	<i>Noel Courage and Lynn C. Tyler</i>	
<b>Chapter 15</b>	Biosimilars in the EU: Regulatory Guidelines.....	395
	<i>Sol Ruiz</i>	
<b>Chapter 16</b>	Biosimilars and Biologics: The Prospects for Competition .....	413
	<i>Erwin A. Blackstone and Joseph P. Fuhr Jr.</i>	
<b>Chapter 17</b>	Plant-Based Production of Biosimilar Drug Products .....	439
	<i>Kenny K. Y. So, Michael R. Marit, J. Christopher Hall, and Michael D. McLean</i>	
<b>Index</b> .....		459